Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Calvez

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Leukemia|November 21, 1998
Lack of evidence of an association between HHV-8 and multiple myelomaD Bouscary, N Dupin, S Fichelson, et al.
The Journal of Antimicrobial Chemotherapy|July 9, 2013
Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and BD B Fofana, C Soulie, A I Maiga, et al.
AIDS (London, England)|October 31, 2001
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failureC Delaugerre, M A Valantin, M Mouroux, et al.
HIV Clinical Trials|November 9, 2012
Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra studyL Schneider, N Ktorza, S Fourati, et al.
HIV Medicine|July 25, 2008
Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot studyH Ait-Mohand, M Bonmarchand, M Guiguet, et al.
The Journal of Antimicrobial Chemotherapy|January 15, 2025
No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimensB Abdi, S Saliba, M Wirden, et al.
The Journal of Antimicrobial Chemotherapy|May 28, 2016
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combinationS Lambert-Niclot, C Allavena, M Grude, et al.
Infection|October 25, 2013
Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity scoreF Caby, L Schneider, C Blanc, et al.
AIDS (London, England)|October 2, 2001
Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide studyD Descamps, V Calvez, J Izopet, et al.
Proceedings. Biological Sciences|March 22, 2013
A mathematical model for mechanotransduction at the early steps of suture formationR H Khonsari, J Olivier, P Vigneaux, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Leukemia|November 21, 1998
Lack of evidence of an association between HHV-8 and multiple myelomaD Bouscary, N Dupin, S Fichelson, et al.
The Journal of Antimicrobial Chemotherapy|July 9, 2013
Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and BD B Fofana, C Soulie, A I Maiga, et al.
AIDS (London, England)|October 31, 2001
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failureC Delaugerre, M A Valantin, M Mouroux, et al.
HIV Clinical Trials|November 9, 2012
Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra studyL Schneider, N Ktorza, S Fourati, et al.
HIV Medicine|July 25, 2008
Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot studyH Ait-Mohand, M Bonmarchand, M Guiguet, et al.
The Journal of Antimicrobial Chemotherapy|January 15, 2025
No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimensB Abdi, S Saliba, M Wirden, et al.
The Journal of Antimicrobial Chemotherapy|May 28, 2016
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combinationS Lambert-Niclot, C Allavena, M Grude, et al.
Infection|October 25, 2013
Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity scoreF Caby, L Schneider, C Blanc, et al.
AIDS (London, England)|October 2, 2001
Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide studyD Descamps, V Calvez, J Izopet, et al.
Proceedings. Biological Sciences|March 22, 2013
A mathematical model for mechanotransduction at the early steps of suture formationR H Khonsari, J Olivier, P Vigneaux, et al.
Pageof 15